- Home
- NXGL vs VYNE Comparison
NXGL vs VYNE Comparison
Compare NXGL & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | VYNE |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 12.5M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NXGL | VYNE |
|---|---|---|
| Price | $1.23 | $0.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.5K | ★ 493.5K |
| Earning Date | 11-11-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,666,000.00 | $524,000.00 |
| Revenue This Year | $39.28 | N/A |
| Revenue Next Year | $42.29 | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.37 | 6.29 |
| 52 Week Low | $1.34 | $0.28 |
| 52 Week High | $3.80 | $2.94 |
Technical Indicators
Market Signals| Indicator | NXGL | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 57.11 |
| Support Level | $1.58 | $0.55 |
| Resistance Level | $1.74 | $0.57 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 6.49 | 39.14 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.